Skip to main content
Faiz Anwer, MD, Oncology, Cleveland, OH, Banner - University Medical Center Tucson

FaizAnwerMD

Oncology Cleveland, OH

Associate Professor, Medicine, University of Arizona College of Medicine

Dr. Anwer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Anwer's full profile

Already have an account?

Summary

  • Dr. Faiz Anwer is an oncologist in Cleveland, OH and is affiliated with Cleveland Clinic Taussig Cancer Center. He specializes in hematologic oncology.

Education & Training

  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2009 - 2012
  • UPMC Medical Education
    UPMC Medical EducationResidency, Internal Medicine, 2004 - 2007
  • Rawalpindi Medical College
    Rawalpindi Medical CollegeClass of 1998

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2018 - 2025
  • CA State Medical License
    CA State Medical License 2018 - 2024
  • AZ State Medical License
    AZ State Medical License 2007 - 2024
  • WA State Medical License
    WA State Medical License Active through 2014
  • PA State Medical License
    PA State Medical License 2004 - 2008
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients
    Faiz Anwer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma
    Faiz Anwer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting
    Faiz Anwer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Network Meta-Analysis of Clinical Trials Assessing Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Among Young Adults 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel Agents
    Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel AgentsFebruary 26th, 2021
  • Multiple Myeloma: Choosing Your Path
    Multiple Myeloma: Choosing Your PathDecember 18th, 2020
  • COVID-19 and Its Psychological Impacts on Healthcare Staff – A Multi-Centric Comparative Cross-Sectional Study
    COVID-19 and Its Psychological Impacts on Healthcare Staff – A Multi-Centric Comparative Cross-Sectional StudyNovember 28th, 2020
  • Join now to see all

Professional Memberships

Hospital Affiliations